Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group

Open access
Schenck, C.H., Montplaisir, J.Y., Frauscher, B., Hogl, B., Gagnon, J.-F., Postuma, R., Sonka, K., Jennum, P., Partinen, M., Arnulf, I., Cochen de Cock, V., Dauvilliers, Y., Luppi, P.-H., Heidbreder, A., Mayer, G., Sixel-Döring, F., Trenkwalder, C., Unger, M., Young, P., Wing, Y.K., Ferini-Strambi, L., Ferri, R., Plazzi, G., Zucconi, M., Inoue, Y., Iranzo, A., Santamaria, J., Bassetti, C., Möller, J.C., Boeve, B.F., Lai, Y.Y., Pavlova, M., Saper, C., Schmidt, P., Siegel, J.M., Singer, C., St Louis, E., Videnovic, A., Oertel, W. · 2013 · Sleep Medicine

Abstract

Objective: To provide a consensus statement by the International Rapid Eye Movement Sleep Behavior Disorder Study Group (IRBD-SG) on devising controlled active treatment studies in rapid eye movement sleep behavior disorder (RBD) and devising studies of neuroprotection against Parkinson disease (PD) and related neurodegeneration in RBD. Methods: The consensus statement was generated during the fourth IRBD-SG symposium in Marburg, Germany in 2011. The IRBD-SG identified essential methodologic components for a randomized trial in RBD, including potential screening and diagnostic criteria, inclusion and exclusion criteria, primary and secondary outcomes for symptomatic therapy trials (particularly for melatonin and clonazepam), and potential primary and secondary outcomes for eventual trials with disease-modifying and neuroprotective agents. The latter trials are considered urgent, given the high conversion rate from idiopathic RBD (iRBD) to Parkinsonian disorders (i.e., PD, dementia with Lewy bodies [DLB], multiple system atrophy [MSA]). Results: Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ≥2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1 to 3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA. Twenty-four exclusion criteria were identified. The primary outcome measure for RBD treatment trials was determined to be the Clinical Global Impression (CGI) efficacy index, consisting of a 4-point scale with a 4-point side-effect scale. Assessment of video-polysomnographic (vPSG) changes holds promise but is costly and needs further elaboration. Secondary outcome measures include sleep diaries; sleepiness scales; PD sleep scale 2 (PDSS-2); serial motor examinations; cognitive indices; mood or anxiety indices; assessment of frequency of falls, gait impairment, and apathy; fatigue severity scale; and actigraphy and customized bed alarm systems. Consensus also was established for evaluating the clinical and vPSG aspects of RBD. End points for neuroprotective trials in RBD taking lessons from research in PD should be focused on the ultimate goal of determining the performance of disease-modifying agents. To date no compound with convincing evidence of disease-modifying or neuroprotective efficacy has been identified in PD. Nevertheless, iRBD patients are considered ideal candidates for neuroprotective studies. Conclusions: The IRBD-SG provides an important platform for developing multinational collaborative studies on RBD, such as on environmental risk factors for iRBD, as recently reported in a peer-reviewed journal article, and on controlled active treatment studies for symptomatic and neuroprotective therapy that emerged during the 2011 consensus conference in Marburg, Germany, as described in our report.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.sleep.2013.02.016

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 234

Metadata

Authors
Schenck, C. H., Montplaisir, J. Y., Frauscher, B., Hogl, B., Gagnon, J.-F., Postuma, R., Sonka, K., Jennum, P., Partinen, M., Arnulf, I., Cochen de Cock, V., Dauvilliers, Y., Luppi, P.-H., Heidbreder, A., Mayer, G., Sixel-Döring, F., Trenkwalder, C., Unger, M., Young, P., Wing, Y. K., Ferini-Strambi, L., Ferri, R., Plazzi, G., Zucconi, M., Inoue, Y., Iranzo, A., Santamaria, J., Bassetti, C., Möller, J. C., Boeve, B. F., Lai, Y. Y., Pavlova, M., Saper, C., Schmidt, P., Siegel, J. M., Singer, C., St Louis, E., Videnovic, A., & Oertel, W.
Venue
Sleep Medicine
Publisher
Elsevier BV
Published
2013-08
Volume
14
Issue
8
Pages
795-806
ISSN
1389-9457 (ISSN-L)
OpenAlex
W2024566803
Cited by
234
References
7
FWCI
13.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. https://app.cochat.ai/papers/10.1016/j.sleep.2013.02.016
The paper
Schenck, C. H., Montplaisir, J. Y., Frauscher, B., Hogl, B., Gagnon, J.-F., Postuma, R., Sonka, K., Jennum, P., Partinen, M., Arnulf, I., Cochen de Cock, V., Dauvilliers, Y., Luppi, P.-H., Heidbreder, A., Mayer, G., Sixel-Döring, F., Trenkwalder, C., Unger, M., Young, P., . . . Oertel, W. (2013). Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Medicine. https://doi.org/10.1016/j.sleep.2013.02.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.